A few days later, after the company opened its doors, a lot of reports say that they have been successful. “The company sold 4.4 million shares for $16 each. Kythera raised $70 million in gross proceeds in the offering process.” They were also doing well at the stock market as they closed at 344 million dollars by October 11th. They only offered 25% of their shares.
Kythera was established around 2005 and it partnered with the famous Bayer, a German company when it tried to reach the offshore market. Both of them have recently finished some tests on ATX-101 in the European continent and the results were great. It went on to the approval of the injectable product. Moreover, tests results in the US and Canada will likely be on mid-2013.
Kythera’s plan is to dominate the facial improvement market because it’s a big piece when it comes to cosmetic and aesthetic market. According to ASAPS or the Society for Aesthetic Plastic Surgery, the field of cosmetic surgery is steadily growing and it has already around 10 billion profit from consumer’s money.
“As long as they keep their products safe for my patients, it will not be a problem to me,” says a renowned plastic surgeon Dr. J from http://drjdallasplasticsurgeon.com/
“The problem with our field sometimes is that it’s highly commercialized and business oriented, the focus on health and safety are being ignored.” Kythera’s product combined with the qualified doctor’s superb ability in using these injectables can lead to a very successful procedure.
We know that there’s a rise in the number of people getting these chin augmentations. However, experts recommend that you consult first with board-certified practitioners before you jump in and get one for your own.